Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
iTeos Therapeutics ( (ITOS) ) has issued an announcement.
On July 18, 2025, iTeos Therapeutics entered into a merger agreement with Concentra Biosciences, where Concentra will acquire iTeos for $10.047 in cash per share plus a contingent value right. The iTeos board has unanimously approved the merger, which is expected to close in the third quarter of 2025, subject to certain conditions including a minimum cash requirement and shareholder approval. This acquisition is seen as beneficial for iTeos’ stockholders and aligns with the company’s strategic goals.
The most recent analyst rating on (ITOS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.
Spark’s Take on ITOS Stock
According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.
iTeos Therapeutics is facing considerable financial difficulties with declining profitability and cash flow issues. Despite some technical momentum, overbought signals and negative corporate events such as the strategic wind down and termination of a major collaboration weigh heavily on the stock’s outlook. The negative P/E ratio and absence of dividends further challenge its valuation.
To see Spark’s full report on ITOS stock, click here.
More about iTeos Therapeutics
iTeos Therapeutics is a biotechnology company headquartered in Watertown, Massachusetts, with an office in Gosselies, Belgium. The company focuses on developing innovative cancer immunotherapies and has a portfolio of product candidates aimed at enhancing the immune system’s ability to fight cancer.
Average Trading Volume: 1,419,184
Technical Sentiment Signal: Hold
Current Market Cap: $392.7M
Learn more about ITOS stock on TipRanks’ Stock Analysis page.